Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 392-398

  Umahara, Takahiko ^a,b   Uchihara, Toshiki ^b   Yamada, Shingo ^c   Hashimoto, Takao ^a   Akimoto, Jiro ^a   Haraoka, Jo ^a   Iwamoto, Toshihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c SHINO TEST CORPORATION   (Japan)

Author keywords

Apolipoprotein(a); Carotid plaque; Oxidized native lipoprotein(a); Plasminogen; Vascular smooth muscle cell

Indexed keywords

FIBRIN; LIPOPROTEIN A; NATIVE LIPOPROTEIN A; OXIDIZED LIPOPROTEIN A; PLASMINOGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKENING; ARTERY INTIMA; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ARTERY; BRAIN ATHEROSCLEROSIS; CADAVER; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBRIN DEPOSITION; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

AGED; AGED, 80 AND OVER; CAROTID ARTERIES; CEREBRAL ARTERIES; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC; PLASMINOGEN;

EID: 79953031235     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.048     Document Type: Article

References (21)

1. Mclean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
2. Tziomalos K., Athyros V.G., Wierzbicki A.S., Mikhailidis D.P. Lipoprotein a: where are we now. Curr Opin Cardiol 2009, 24:351-357.
3. Smolders B., Lemmens R., Thijs V. Lipoprotein(a) and stroke; A meta-analysis of observational studies. Stroke 2007, 38:1959-1966.
4. Petersen N.H., Schmied A.B., Zeller J.A., Plendl H., Deuschl G., Zunker P. Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. Cerebrovasc Dis 2007, 23:188-193.
5. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989, 339:303-305.
6. Yamada S., Morishita R., Nakamura S., et al. Development of antibody against epitope of lipoprotein(a) modified by oxidation: enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation 2000, 102:1639-1644.
7. Komori N., Morishita R., Yamada S., et al. Mitogenic activity of oxidized lipoprotein(a) on human vascular smooth muscle cells. Hypertension 2002, 40:310-314.
8. Morishita R., Ishii J., Kusumi Y., et al. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. J Atheroscler Thromb 2009, 16:410-418.
9. Song R., Ricky Y.K., Man Angel A, Sheng X. Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis 1997, 128:1-10.
10. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995, 15:1512-1531.
11. Jamieson D.G., Usher D.C., Rader D.J., Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels: a potential role for endothelial cells in lesion formation. Am J Pathol 1995, 147:1567-1574.
12. Lou X.J., Boonmark N.W., Horrigan F.T., Degen J.L., Lawn R.M. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998, 95:12591-12595.
13. Sotiriou S.N., Orlova V.V., Al-Fakhri N., et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006, 20:559-561.
14. Virmani R., Kolodgie F.D., Bruke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
15. 2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2094-2099.
16. Vickers K.C., Castro-Chavez F., Morrisett J.D. Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells. Atherosclerosis 2010, 211:122-129.
17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
18. Ichikawa T., Unoki H., Sun H., et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesion of human apo(a) transgenic rabbits. Am J Pathol 2002, 160:227-236.
19. Owens G.K., Loeb A., Gordon D., Thompson M.M. Expression of smooth muscle-specific α-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 1986, 102:343-352.
20. Grainger D.J., Kirscheniohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993, 260:1655-1658.
21. Grainger D.J., Kemp P.R., Lawn R.M., Metcalfe J.C. Activation of transforming factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370:460-462.